Skip to content
SPY$715.87down −1.96%
Nasdaq$645.04down −2.19%
Nvidia$145.98down −3.30%
SpaceX$138.43down −3.53%
BTC$61,334.00down −2.16%
Gold$3,540.71down −5.30%
Silver$42.30down −8.22%
Brent oil$92.50up +0.37%
DXY103.72down −0.07%
EUR/USD1.0964down −0.09%
USD/JPY159.30down −0.29%
2Y yield4.76%down −4 bp
5Y yield4.86%down −3 bp
10Y yield5.04%down −3 bp

Search FinPrism

Companies · · 3 min read

Editor: Bohdan S.

Novo Nordisk lifts 2026 forecast again as Wegovy pill sales beat estimates

The Danish drugmaker's new weight-loss tablet brought in DKK 5.4bn in the third quarter, helping it raise guidance again after an August upgrade. Shares rose, though the stock is still down for 2026.

Novo Nordisk lifts 2026 forecast again as Wegovy pill sales beat estimates

The short answer

Novo Nordisk raised its 2026 sales and profit forecasts after third-quarter results beat analyst estimates, helped by DKK 5.4 billion of Wegovy pill sales. The Financial Times (FT) reported that demand for its GLP-1 drugs was stronger than expected. Shares rose as much as 6%, but the company still expects roughly flat sales this year.

What happened

Novo Nordisk said on Wednesday that third-quarter sales reached DKK 79.2 billion, about $11.9 billion, a 4% rise at constant exchange rates (which strip out currency swings). Adjusted operating profit jumped 27% on that basis to DKK 31.7 billion. Both numbers came in above FactSet consensus forecasts, CNBC reported. The Wegovy pill alone brought in DKK 5.4 billion, against roughly DKK 4.5 billion expected by analysts. Novo now sees 2026 adjusted sales and adjusted operating profit each moving between a 2% fall and a 2% rise, better than the zero to minus 6% range it gave in August. The Financial Times (FT) reported that GLP-1 demand had exceeded expectations.

What it means

The headline here is the pill. Wegovy has been sold for years as a weekly injection, and Novo began selling a tablet version earlier in 2026. By the end of the third quarter it was available in eight markets, according to Novo, and its sales already amount to about a quarter of what injectable Wegovy earned in the same period (DKK 20.4 billion, per CNBC). Diabetes drug Ozempic, which uses the same active ingredient, semaglutide, brought in DKK 29.7 billion. Both injectables also beat expectations. A pill matters because many people who would never start weekly injections may be willing to take a tablet.

Context explains why investors cared so much. Novo pioneered GLP-1 drugs, a class that mimics a gut hormone to curb appetite and control blood sugar, but CNBC noted it lost ground this year as rival Eli Lilly caught up and overtook it in the US, the biggest market. Lilly also raised its own forecast last week, while its weight-loss pill Foundayo fell short of analyst hopes for the quarter. Against that backdrop, Novo's beat suggests its tablet has made a strong early start in the pill race.

Some of the headline strength needs a closer look. The 27% jump in adjusted profit was flattered by restructuring costs booked a year earlier, Novo said. On a reported basis, operating profit actually fell 9% to DKK 23.0 billion, dragged down by DKK 8.7 billion of non-cash impairments, which are write-downs in the value of assets such as pipeline drugs. And even the upgraded guidance still centers on roughly flat sales for the full year, so this is a recovery from a weak start rather than a return to the rapid growth of earlier years.

Chief executive Mike Doustdar struck a cautious tone himself. "Turnaround and recovery is not done based on one data point," he told reporters, according to CNBC. The next test is CagriSema, a combination drug that produced 21% weight loss at week 68 in a trial called REDEFINE 9. Novo is preparing to launch it in the US in early 2027, subject to regulatory approval. The company also named a new finance chief: Karsten Munk Knudsen will step down as CFO at the end of 2026 and be replaced by Luigi La Corte, currently CFO at Galderma.

The bull case

Supporters would point to a second guidance upgrade since August and a pill that is selling faster than analysts modeled, which could widen the pool of patients beyond those willing to inject. Injectable Wegovy and Ozempic also beat forecasts, and Novo continues to buy back shares, with up to DKK 15 billion planned over the 12 months that began in February, according to company notices. A CagriSema launch in 2027 could add another leg of growth.

The bear case

Skeptics would note that full-year sales are still expected to be about flat, reported profit fell, and impairments keep piling up. Citi kept a neutral rating after the results, CNBC reported, citing uncertainty over weight-loss drug pricing and the lack of a clear successor to Wegovy. Analysts have also questioned CagriSema's commercial appeal after it failed to beat Lilly's existing drugs, and competition from Lilly and other drugmakers is intensifying.

Why it matters

For investors

Novo's beat puts the obesity-drug trade back in focus, along with its US-listed shares and Lilly as the main rival. Its Copenhagen shares were last up 3.4% on the day, leaving them roughly 13% lower so far this year, CNBC reported.

The wider context

Anyone holding healthcare funds that own Novo or Lilly is exposed to this race. The results also suggest weight-loss pills could become a big, mainstream market, which may affect how these treatments are priced and accessed.

Market impact

Asset (ticker)Possible moveTimeframeWhy
Novo Nordisk (NVO) ↑ Up Short term Results and Wegovy pill sales beat estimates and guidance rose, lifting shares as much as 6%.

The FinPrism newsroom's view of how these figures could move, as of . It is general news commentary, not a recommendation to buy, sell or hold anything.

Frequently asked questions

How much did the Wegovy pill sell in the third quarter?

Novo Nordisk said its Wegovy pill generated DKK 5.4 billion of sales in the third quarter of 2026, ahead of the roughly DKK 4.5 billion analysts expected, according to CNBC. The tablet had launched in eight markets by the time of the results.

What is Novo Nordisk's new 2026 outlook?

Novo now expects 2026 adjusted sales and adjusted operating profit to each change by between minus 2% and plus 2% at constant exchange rates. In August it had guided to a range of zero to minus 6%. The company said higher expectations for GLP-1 sales drove the upgrade.

Why did Novo Nordisk stock rise after its results?

Shares climbed as much as 6% because third-quarter sales, adjusted profit and Wegovy pill revenue all came in above analyst forecasts and the company raised its full-year guidance. Even after the gain, Copenhagen-listed shares were still down about 13% for the year, CNBC reported.

Sources: Financial Times, Novo Nordisk company announcements (Stock Titan), CNBC

How this was made: written with AI assistance from the sources listed above, following our editorial standards.

Back to the latest